Terms: = Uterine cancer AND MYH11, ENSG00000133392, 4629
4 results:
1. Investigating the potential of Juglans regia phytoconstituents for the treatment of cervical cancer utilizing network biology and molecular docking approach.
Dua R; Bhardwaj T; Ahmad I; Somvanshi P
PLoS One; 2024; 19(4):e0287864. PubMed ID: 38626166
[TBL] [Abstract] [Full Text] [Related]
2. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract] [Full Text] [Related]
3. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract] [Full Text] [Related]
4. Therapy-related leukemia with Inv(16)(p13.1q22) and type D CBFB/myh11 developing after exposure to irinotecan-containing chemoradiotherapy.
Akiyama H; Yamamoto M; Sakashita C; Umezawa Y; Kurosu T; Murakami N; Miura O
Intern Med; 2015; 54(6):651-5. PubMed ID: 25786458
[TBL] [Abstract] [Full Text] [Related]
